Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · IEX Real-Time Price · USD
5.51
-0.30 (-5.16%)
May 17, 2024, 4:00 PM EDT - Market closed
Foghorn Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for FHTX stock have an average target of 14.5, with a low estimate of 6.00 and a high estimate of 20. The average target predicts an increase of 163.16% from the current stock price of 5.51.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for FHTX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +262.98% | May 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +262.98% | May 1, 2024 |
| Wedbush | Wedbush | Buy Reiterates $13 | Buy | Reiterates | $13 | +135.93% | Apr 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +262.98% | Apr 10, 2024 |
| Wedbush | Wedbush | Buy Reiterates $13 | Buy | Reiterates | $13 | +135.93% | Mar 8, 2024 |
Financial Forecast
Revenue This Year
29.81M
from 34.16M
Decreased by -12.73%
Revenue Next Year
34.84M
from 29.81M
Increased by 16.89%
EPS This Year
-2.17
from -2.34
EPS Next Year
-1.36
from -2.17
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 52.5M | 63.0M | 67.2M | 345.3M | 610.9M |
| Avg | 29.8M | 34.8M | 39.5M | 170.4M | 311.2M |
| Low | n/a | n/a | n/a | 76.3M | 158.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 53.7% | 111.4% | 92.9% | 773.2% | 258.6% |
| Avg | -12.7% | 16.9% | 13.5% | 330.8% | 82.7% |
| Low | - | - | - | 93.1% | -6.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.89 | -0.58 | -1.00 | -0.78 | 0.42 |
| Avg | -2.17 | -1.36 | -1.69 | -1.30 | -0.10 |
| Low | -2.48 | -2.14 | -2.20 | -1.80 | -0.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.